close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,164.35 +48.67 (+4.36%)
Streaming Delayed Price Updated: 1:51 PM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Stock Market Midday, Aug. 5: Eli Lilly Pops and AMD Drops in Mixed Morning Markets ↗
On Aug. 5, 2026, new highs across major indexes reflect renewed confidence in global trade as investor confidence starts to return. 
Via The Motley Fool
Topics Artificial Intelligence Earnings Stocks
Top S&P500 movers in Wednesday's session ↗
Via Chartmill
News headline image
Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion ↗
Eli Lilly (LLY) beat Q2 earnings expectations & raised 2026 guidance as Mounjaro and Zepbound drove $22.97B in revenue. Read more. 
Via Benzinga
News headline image
Eli Lilly (LLY) Stock Trades Up, Here Is Why
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.5% in the morning session after the company delivered a massive "beat an... 
Via StockStory
Eli Lilly (NYSE:LLY) Stands Out as a High-Growth Momentum Leader ↗
Via Chartmill
News headline image
Nasdaq Falls Over 100 Points; Eli Lilly Shares Gain On Upbeat Earnings ↗
Stocks mixed as Nasdaq falls 100 points, Dow rises .79%. Eli Lilly beats earnings estimates, Digital Turbine surges 43%, oil down .4%, gold up 2.5% 
Via Benzinga
Topics Stocks
News headline image
The FTC Is Suing Hims & Hers Health—Here's Why Investors Shouldn't Panic ↗
Hims & Hers Health shares have rallied despite an FTC lawsuit over data sharing and billing practices, as weight-loss drug partnerships and Wall Street's cautious Hold rating shape the stock's outlook... 
Via MarketBeat
Topics Lawsuit
News headline image
CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal ↗
CVS Health beats Q2 earnings expectations and hikes FY26 guidance, but shares fall on profit-taking. Get the full financial breakdown. 
Via Benzinga
Which S&P500 stocks are gapping on Wednesday? ↗
Via Chartmill
News headline image
Eli Lilly's Diabetes And Obesity Drugs Blow Past Expectations; Shares Pop ↗
Eli Lilly stock jumped Wednesday on a solid beat-and-raise thanks to its GLP-1 drugs, treatments for diabetes and obesity. 
Via Investor's Business Daily
Wondering what's happening in today's S&P500 pre-market session? ↗
Via Chartmill
News headline image
Eli Lilly (NYSE:LLY) Beats Expectations in Strong Q2 CY2026, Full-Year Outlook Slightly Exceeds Expectations
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 47.7% year on year t... 
Via StockStory
News headline image
Elanco’s (NYSE:ELAN) Q2 CY2026: Strong Sales, Stock Soars
Animal health company Elanco (NYSE:ELAN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 10.2% year on year to $1.37 billion... 
Via StockStory
News headline image
AMD, Walt Disney And 3 Stocks To Watch Heading Into Wednesday ↗
U.S. stock futures up, Eli Lilly, AMD, Disney, SpaceX and SanDisk expected to release earnings. SpaceX beats estimates, shares down 7.5%. 
Via Benzinga
News headline image
$100 Invested In Eli Lilly 20 Years Ago Would Be Worth This Much Today ↗
Eli Lilly (NYSE:LLY) has outperformed the market over the past 20 years by 6.87% on an annualized basis producing an average annual return of 16.31%. Currently, Eli Lilly has a market capitalization of... 
Via Benzinga
News headline image
Eli Lilly Could Swing $65.9 Billion After Earnings ↗
Earnings coming Wed with varying volatility levels. Benzinga Pro selected list incl. relatively muted setups to double-digit swings. Top pick Eli Lilly. 
Via Benzinga
News headline image
How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings ↗
Eli Lilly investors may be eyeing potential gains from the company’s annual dividend yield of 0.62% ($6.92 a year). 
Via Benzinga
News headline image
Eli Lilly Is Up 7% in 2026 and Has Major Catalysts on the Way. Is the Rally Just Getting Started? ↗
Eli Lilly's key catalyst for 2027 could positively affect price action sooner than you think. 
Via The Motley Fool
News headline image
Amazon and Microsoft Gained a Combined $1.04 Trillion in Market Cap in 2 Days, While Apple and Meta Platforms Lost $510 Billion. Meet the Vanguard ETF That's Built for This Exact Market. ↗
With volatility heating up, some investors may prefer the straightforward approach of the Vanguard Mega Cap Growth ETF. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
News headline image
What To Expect From Eli Lilly’s (LLY) Q2 Earnings
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results this Wednesday morning. Here’s what investors should know. Eli Lilly beat analys... 
Via StockStory
Topics Artificial Intelligence
News headline image
Inspire Medical Systems Q2 Earnings Call Highlights ↗
Inspire Medical Systems (NYSE:INSP) reported second-quarter revenue of $200.6 million, down 7.6% from a year earlier, as coding and reimbursement disruptions continued to affect procedure volumes. The... 
Via MarketBeat
Topics Earnings
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Is Eli Lilly Stock Running out of Steam? ↗
The healthcare stock is up over 300% in five years and has a market cap of around $1 trillion. 
Via The Motley Fool
News headline image
Eli Lilly Could Swing Over $76 Billion In Value After Earnings ↗
Earnings season is approaching, and Benzinga Pro has a list of top stocks to watch. Gilead Sciences and Uber Technologies are expected to have significant market moves based on their upcoming earnings... 
Via Benzinga
News headline image
Which Is the Better State Street Healthcare ETF: The Broad XLV or the Biotech XBI? ↗
XBI surged 76% in one year but carries triple the expense ratio and far steeper downside risk. Which fund matches your risk appetite? 
Via The Motley Fool
Topics ETFs
News headline image
Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? ↗
Abbott trades at half Lilly's valuation multiple, but Lilly's 45% revenue surge and 32% net margin raise the stakes for growth-focused investors. 
Via The Motley Fool
News headline image
XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy? ↗
IBBQ posted the stronger return over the past year, but has also experienced much higher historical volatility than XLV. 
Via The Motley Fool
Topics ETFs Intellectual Property
News headline image
Prediction: Eli Lilly Will Be Worth $2 Trillion by 2031 ↗
And it will likely be the first company in the sector to get there. 
Via The Motley Fool
News headline image
XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist? ↗
PBE surged 41% in one year but endured a 35% drawdown, while XLV's diversified approach delivered steadier gains with half the volatility. 
Via The Motley Fool
Topics ETFs
News headline image
Healthcare Stocks Are Having a Good Year. Should You Buy a Fidelity or iShares ETF to Profit? ↗
FHLC holds 334 positions versus IYH's 100, yet both delivered similar five-year returns despite their structural differences. 
Via The Motley Fool
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.